alendronate has been researched along with Hip Fractures in 143 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Hip Fractures: Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 140 postmenopausal women or men aged older than 50 years who met the indications for osteoporosis treatment were randomized to receive either generic (Bonmax®) or brand alendronate (Fosamax®) 70 mg/week over a 12-month period during the May 2014 to June 2015 study period." | 9.24 | Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment. ( Jarusriwanna, A; Songcharoen, P; Unnanuntana, A, 2017) |
| "To assess efficacy and safety of alendronate sodium treatment in osteoporosis patients with hip fracture." | 9.11 | [Clinic effect of alendronate sodium treatment in osteoporosis patients with hip fracture]. ( Jin, J; Lin, J; Luo, XZ; Qiu, GX; Shen, JX; Tang, H; Tian, Y; Wang, YP; Weng, XS; Wu, ZH; Yang, XY; Zhang, JG; Zhao, H, 2004) |
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 7.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| "Subtrochanteric femoral fractures associated with long-term alendronate therapy present with minimal trauma, may be chronic, and when incomplete may be missed." | 7.76 | Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. ( Capeci, C; Chan, K; Chan, SS; Rosenberg, ZS, 2010) |
| "Treatment with alendronate, a potent and specific inhibitor of bone resorption, is known to significantly reduce fracture risk among women with postmenopausal osteoporosis." | 6.43 | Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. ( Hochberg, MC; Liberman, UA; Papapoulos, SE; Quandt, SA; Thompson, DE, 2005) |
| " Among patients with osteoporosis in Taiwan who had experienced a fracture and had started alendronate therapy, compliance with the dosage regimen was suboptimal." | 5.37 | Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. ( Lin, SJ; Lin, TC; Yang, CY; Yang, YH, 2011) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 5.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| "A total of 140 postmenopausal women or men aged older than 50 years who met the indications for osteoporosis treatment were randomized to receive either generic (Bonmax®) or brand alendronate (Fosamax®) 70 mg/week over a 12-month period during the May 2014 to June 2015 study period." | 5.24 | Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment. ( Jarusriwanna, A; Songcharoen, P; Unnanuntana, A, 2017) |
| "These data show that weekly systemic administration of alendronate improves pin fixation in cancellous bone in elderly female patients with osteoporosis." | 5.12 | Alendronate improves screw fixation in osteoporotic bone. ( Faldini, C; Giannini, S; Hoang-Kim, A; Moroni, A; Pegreffi, F, 2007) |
| " The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD." | 5.12 | Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. ( Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K, 2006) |
| "To assess efficacy and safety of alendronate sodium treatment in osteoporosis patients with hip fracture." | 5.11 | [Clinic effect of alendronate sodium treatment in osteoporosis patients with hip fracture]. ( Jin, J; Lin, J; Luo, XZ; Qiu, GX; Shen, JX; Tang, H; Tian, Y; Wang, YP; Weng, XS; Wu, ZH; Yang, XY; Zhang, JG; Zhao, H, 2004) |
| "Randomized controlled trials in postmenopausal women receiving alendronate or placebo for preventing hip fractures rate were searched from Medline, EMBASE, Cochrane Trial Registry and China Biological Medicine database between January 1980 to December 2007." | 4.85 | [Meta-analysis of alendronate preventing hip fracture risk of postmenopausal women]. ( Li, XL; Shi, HP; Yuan, T; Zeng, BF; Zhang, CQ, 2009) |
| "According to the data of a fracture intervention trial, in women aged 55-80 years with vertebral fractures or osteoporosis diagnosed by bone mineral density measurement, treatment with the bisphosphonate alendronate prevented hip fractures with numbers-needed-to-treat within 5 years of treatment of 46 and 66, respectively." | 4.81 | [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures]. ( Netelenbos, JC, 2001) |
| "Our results demonstrate that alendronate reduces the risk of vertebral, non vertebral and hip fractures in postmenopausal women with low bone mass." | 4.80 | [Effect of alendronate on bone mineral density and incidence of fractures in postmenopausal women with osteoporosis. A meta-analysis of published studies]. ( Arboleya, LR; Fiter, J; Morales, A, 2000) |
| " Four drugs, calcium, calcitonin, estrogen, and alendronate have been approved for marketing by the Food and Drug Administration for the treatment of osteoporosis." | 4.80 | Medical management of osteoporosis. Fracture prevention. ( Brunelli, MP; Einhorn, TA, 1998) |
| " Cohorts consisted of 92 355 individuals 50 years or older who were new users of denosumab (n = 4624) or alendronate (n = 87 731) from May 2010 to December 2017 after at least 1 year without an antiosteoporosis medication dispensing." | 3.91 | Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation. ( Ehrenstein, V; Heide-Jørgensen, U; Pedersen, AB; Prieto-Alhambra, D; Sørensen, HT, 2019) |
| "There is high evidence for secondary prevention of fractures, including hip fracture, with alendronate treatment, but alendronate's efficacy to prevent hip fractures in the oldest-old (≥80 years old), the population with the highest fracture risk, has not been studied." | 3.85 | Hip fracture risk and safety with alendronate treatment in the oldest-old. ( Axelsson, KF; Johansson, H; Lorentzon, M; Lundh, D; Wallander, M, 2017) |
| "34 years), there were 27 hip fractures in the alendronate group and 73 in the no-alendronate group, corresponding to incidence rates of 9." | 3.85 | Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone. ( Axelsson, KF; Lorentzon, M; Lundh, D; Nilsson, AG; Wedel, H, 2017) |
| "Using previous data from Taiwan and literature, we determined cost-effectiveness thresholds for prevention of osteoporotic fractures by alendronate with a Markov model, as well as using two other translational approaches." | 3.85 | Establishing and evaluating FRAX ( Chan, DC; Chang, CB; Lim, LC; Lin, KP; McCloskey, EV; Tsai, KS; Yang, RS, 2017) |
| " Assuming a willingness to pay (WTP) of €32,000 per quality-adjusted life years (QALYs), treatment with generic alendronate is cost effective for men and women aged 50 years or more, with 10-year probabilities for major osteoporotic fractures and hip above 8." | 3.83 | Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal. ( Borgström, F; da Silva, JA; Kanis, JA; Lourenço, Ó; Marques, A; Ortsäter, G, 2016) |
| " Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures." | 3.81 | Efficacy, effectiveness and side effects of medications used to prevent fractures. ( Reid, IR, 2015) |
| "While alendronate inhibits atherosclerosis experimentally, its effect on lower limb ischemia risk is unknown." | 3.80 | Alendronate and risk of lower limb ischemic vascular events: a population-based cohort study. ( Chang, HL; Chang, HT; Chen, CK; Chen, TJ; Chen, YC; Chou, HP; Huang, YC; Lee, MH; Shih, CC, 2014) |
| " Medicines dispensed at a pharmacy which are indicated for the prevention of osteoporotic hip fractures (alendronate, risedronate and strontium ranelate)." | 3.77 | [Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain]. ( Charle-Crespo, MÁ; Gomes-Carvalho, CS; Guerra-García, MM; Prejigueiro-Santás, A; Puga-Sarmiento, E; Rodríguez-Fernández, JB, 2011) |
| "For hip fractures, there was statistically significant interaction with alendronate for PPI use (P < ." | 3.77 | Proton pump inhibitor use and the antifracture efficacy of alendronate. ( Abrahamsen, B; Eastell, R; Eiken, P, 2011) |
| "The goal of this study was to evaluate the benefits of alendronate in preventing rehospitalization due to hip fractures and whether its use increases risk of hospitalization for atypical diaphyseal femoral fractures in Taiwan." | 3.77 | Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women. ( Chen, LK; Chen, YM; Hsiao, FY; Huang, WF; Kao, YH; Tsai, YW; Wen, YW, 2011) |
| "One of the patients was treated with alendronate therapy in concern of her risk factors for osteoporosis (her previous a hysterectomy with bilateral oophorectomy) with unsubstantiated evidence of her pretreatment, bone-mineral-density measurements (BMD), for a 10-year prior episode of left prodromal thigh pain and an insufficiency fracture at 8 days post experiencing the pain." | 3.77 | Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases. ( Angthong, C; Angthong, W, 2011) |
| "Subtrochanteric femoral fractures associated with long-term alendronate therapy present with minimal trauma, may be chronic, and when incomplete may be missed." | 3.76 | Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. ( Capeci, C; Chan, K; Chan, SS; Rosenberg, ZS, 2010) |
| "No BMD test or alendronate therapy, a BMD test followed by selective alendronate therapy for patients with osteoporosis, or universal alendronate therapy without a BMD test." | 3.76 | Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. ( Elkin, EB; Girotra, M; Ito, K; Morris, MJ, 2010) |
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 3.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| "We developed a decision analytic Markov model to compare the effects of alendronate therapy, raloxifene therapy, and HRT on risks of hip fracture, coronary heart disease (CHD), breast cancer, and life expectancy." | 3.70 | Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. ( Col, NF; Eckman, MH; Goldberg, RJ; Orr, RK; Pauker, SG; Ross, EM; Wong, JB, 1999) |
| "Alendronate-treated women with at least a 30% reduction in bone ALP had a lower risk of non-spine (RH = 0." | 2.71 | Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. ( Bauer, DC; Black, DM; Delmas, PD; Ewing, SK; Garnero, P; Hochberg, M; Orloff, J; Ott, S; Thompson, DE, 2004) |
| " Glucocorticoid (GC) dosage (P = ." | 2.66 | Meta-regression analysis of the efficacy of alendronate for prevention of glucocorticoid-induced fractures. ( Ding, L; Huang, H; Li, K; Lin, J; Qiu, M; Zhang, M, 2020) |
| "Alendronate was the most prescribed drug (more than 30% over the observation period); however, vDCa was seldom prescribed." | 2.66 | Cumulative network meta-analyses, practice guidelines, and actual prescriptions for postmenopausal osteoporosis: a meta-epidemiological study. ( Chaimani, A; Cipriani, A; Furukawa, TA; Kataoka, Y; Kimachi, M; Li, T; Luo, Y; Murad, MH; Onishi, A; Tsujimoto, Y, 2020) |
| "In women with osteopenia or osteoporosis, 6 years of zoledronic acid reduced clinical fractures (HR, 0." | 2.61 | Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. ( Brasure, M; Butler, M; Ensrud, KE; Fink, HA; Forte, ML; MacDonald, R; Nelson, VA; Olson, CM; Rosebush, CE; Schousboe, JT; Taylor, BC; Ullman, K; Wilt, TJ, 2019) |
| "Many drugs for the treatment of osteoporosis have also been associated with increased risks of serious adverse events." | 2.52 | Osteoporosis: the emperor has no clothes. ( Aspenberg, P; Järvinen, TL; Michaëlsson, K; Sievänen, H, 2015) |
| "In particular, hip fractures are an important cause of mortality and morbidity among postmenopausal women." | 2.44 | Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T, 2008) |
| "Treatment with alendronate, a potent and specific inhibitor of bone resorption, is known to significantly reduce fracture risk among women with postmenopausal osteoporosis." | 2.43 | Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. ( Hochberg, MC; Liberman, UA; Papapoulos, SE; Quandt, SA; Thompson, DE, 2005) |
| " In addition, alendronate was shown to have no adverse effects on bone mineralization or microstructure." | 2.40 | Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy. ( Adachi, JD, 1998) |
| "Alendronate use was associated with a lower risk of nonvertebral fracture, including hip fracture." | 1.48 | Alendronate Use and the Risk of Nonvertebral Fracture During Glucocorticoid Therapy: A Retrospective Cohort Study. ( Bergman, J; Nordström, A; Nordström, P, 2018) |
| "It seems reasonable to assume a causative relationship between a long term use of bisphosphonates and the occurrence of atypical hip fractures." | 1.46 | [BISPHOSPHONATES AS A PREVENTATIVE TREATMENT FOR OSTEOPOROTIC HIP FRACTURES: A MIXED BLESSING]. ( Arami, A; Barak, U; Kosashvili, Y; Rosenthal, Y; Velkes, S, 2017) |
| "Osteoporotic intertrochanteric fractures result in serious health problems and decrease health-related quality of life (HRQoL)." | 1.43 | Teriparatide Improves Fracture Healing and Early Functional Recovery in Treatment of Osteoporotic Intertrochanteric Fractures. ( Chuang, PY; Hsu, RW; Huang, KC; Huang, TW; Lee, CY; Lee, MS; Lin, SJ; Shen, WJ; Shih, HN, 2016) |
| "Bisphosphonates are effective for the treatment of osteoporosis despite recent reports of safety concerns such as atypical femur fracture." | 1.42 | Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis. ( Bhattacharyya, T; Jha, S; Laucis, N; Wang, Z, 2015) |
| "Many postmenopausal women have osteopenia, a condition characterized by loss of bone mineral density (BMD) that is not as severe as in osteoporosis." | 1.39 | Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. ( Fukagawa, M; Inoue, H; Komaba, H; Moriwaki, K; Noto, S; Takahashi, HE; Takiguchi, T; Toujo, T; Yanagisawa, S, 2013) |
| " During her most recent gynecology visit, she expressed concern about unusual femoral fractures being linked to long-term use of alendronate." | 1.39 | Menopause practitioner perspective on the American Society of Bone and Mineral Research Task Force report on atypical femoral fracture. ( Ettinger, B; Schnatz, PF; Stuenkel, CA, 2013) |
| "We observed three cohorts of women aged 65 years and older who initiated once-a-week dosing of bisphosphonate therapy; (1) patients adherent to alendronate (n = 21,615), (2) patients adherent to risedronate (n = 12,215), or (3) patients filling only a single bisphosphonate prescription (n = 5,390) as a referent population." | 1.39 | Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2013) |
| " We did not find evidence for a reversal of fracture protection with long-term use of bisphosphonates." | 1.38 | Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. ( Abrahamsen, B; Pazianas, M; Russell, RG; Wang, Y, 2012) |
| " Among patients with osteoporosis in Taiwan who had experienced a fracture and had started alendronate therapy, compliance with the dosage regimen was suboptimal." | 1.37 | Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. ( Lin, SJ; Lin, TC; Yang, CY; Yang, YH, 2011) |
| "Hip fractures are important because they are associated with an increased rate of death, substantial morbidity, enormous costs, and devastating effects on independence and quality of life." | 1.37 | Bisphosphonate-related subtrochanteric femoral fractures. ( Baxter, M; Gunawardena, I; Rasekh, Y, 2011) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 1.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| "Universal bone densitometry combined with alendronate therapy for those found to have osteoporosis is highly cost-effective for women aged 65 and older and may be cost saving for ambulatory women aged 85 and older (whether independently living or residing in nursing homes)." | 1.33 | Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. ( Ensrud, KE; Kane, RL; Melton, LJ; Nyman, JA; Schousboe, JT, 2005) |
| "Hip fractures are the most costly and best-documented complication of osteoporosis." | 1.32 | Health-economic comparison of three recommended drugs for the treatment of osteoporosis. ( Brecht, JG; Huppertz, E; Kruse, HP; Möhrke, W; Oestreich, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (7.69) | 18.2507 |
| 2000's | 56 (39.16) | 29.6817 |
| 2010's | 69 (48.25) | 24.3611 |
| 2020's | 7 (4.90) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, S | 1 |
| Zhao, W | 1 |
| Du, D | 1 |
| Zhang, C | 1 |
| Zhao, T | 1 |
| Zheng, L | 1 |
| Jin, L | 1 |
| Gu, M | 1 |
| Xu, J | 1 |
| Yang, Z | 1 |
| Gates, M | 1 |
| Pillay, J | 1 |
| Nuspl, M | 1 |
| Wingert, A | 1 |
| Vandermeer, B | 1 |
| Hartling, L | 1 |
| Everts-Graber, J | 1 |
| Bonel, H | 1 |
| Lehmann, D | 1 |
| Gahl, B | 1 |
| Häuselmann, H | 1 |
| Studer, U | 1 |
| Ziswiler, HR | 1 |
| Reichenbach, S | 1 |
| Lehmann, T | 1 |
| Kataoka, Y | 1 |
| Luo, Y | 1 |
| Chaimani, A | 1 |
| Onishi, A | 1 |
| Kimachi, M | 1 |
| Tsujimoto, Y | 1 |
| Murad, MH | 1 |
| Li, T | 1 |
| Cipriani, A | 1 |
| Furukawa, TA | 1 |
| Chen, YJ | 1 |
| Kung, PT | 1 |
| Chou, WY | 1 |
| Tsai, WC | 1 |
| Lin, YC | 1 |
| Lee, TC | 1 |
| Chen, CY | 1 |
| Lin, SJ | 3 |
| Hwang, SJ | 1 |
| Lin, MY | 1 |
| Qiu, M | 1 |
| Ding, L | 1 |
| Zhang, M | 1 |
| Lin, J | 2 |
| Huang, H | 1 |
| Li, K | 1 |
| Albert, SG | 1 |
| Reddy, S | 1 |
| Unnanuntana, A | 2 |
| Jarusriwanna, A | 1 |
| Songcharoen, P | 1 |
| Axelsson, KF | 3 |
| Nilsson, AG | 2 |
| Wedel, H | 1 |
| Lundh, D | 2 |
| Lorentzon, M | 4 |
| Barak, U | 1 |
| Rosenthal, Y | 1 |
| Arami, A | 1 |
| Kosashvili, Y | 1 |
| Velkes, S | 1 |
| Wallander, M | 1 |
| Johansson, H | 1 |
| Abrahamsen, B | 5 |
| Desai, RJ | 1 |
| Franklin, JM | 1 |
| Kim, SC | 1 |
| Bergman, J | 1 |
| Nordström, A | 1 |
| Nordström, P | 1 |
| Mathonet, PY | 1 |
| Willems, S | 1 |
| Ciornohac, JF | 1 |
| Sing, CW | 2 |
| Wong, AY | 2 |
| Kiel, DP | 2 |
| Cheung, EY | 2 |
| Lam, JK | 2 |
| Cheung, TT | 2 |
| Chan, EW | 2 |
| Kung, AW | 2 |
| Wong, IC | 2 |
| Cheung, CL | 2 |
| Tran, TS | 1 |
| Nguyen, TV | 1 |
| Pedersen, AB | 1 |
| Heide-Jørgensen, U | 1 |
| Sørensen, HT | 1 |
| Prieto-Alhambra, D | 1 |
| Ehrenstein, V | 1 |
| Fink, HA | 2 |
| MacDonald, R | 1 |
| Forte, ML | 1 |
| Rosebush, CE | 1 |
| Ensrud, KE | 4 |
| Schousboe, JT | 2 |
| Nelson, VA | 1 |
| Ullman, K | 1 |
| Butler, M | 1 |
| Olson, CM | 1 |
| Taylor, BC | 1 |
| Brasure, M | 1 |
| Wilt, TJ | 1 |
| Lindsay, R | 2 |
| Watts, NB | 3 |
| Lange, JL | 3 |
| Delmas, PD | 3 |
| Silverman, SL | 3 |
| Chen, CK | 1 |
| Chang, HT | 1 |
| Chou, HP | 1 |
| Lee, MH | 1 |
| Chen, YC | 1 |
| Huang, YC | 1 |
| Chen, TJ | 1 |
| Chang, HL | 1 |
| Shih, CC | 1 |
| Ettinger, B | 1 |
| Stuenkel, CA | 1 |
| Schnatz, PF | 1 |
| Serrano, AJ | 1 |
| Begoña, L | 1 |
| Anitua, E | 1 |
| Cobos, R | 1 |
| Orive, G | 1 |
| Vaishya, R | 1 |
| Vaish, A | 1 |
| Nadeem, A | 1 |
| Ward, JP | 1 |
| Strauss, EJ | 1 |
| Tejwani, NC | 1 |
| O'Neill, BJ | 1 |
| O'hEireamhoin, S | 1 |
| Morrissey, DI | 1 |
| Keogh, P | 1 |
| Özsoy, MH | 1 |
| Aksekili, MA | 1 |
| Kızılay, O | 1 |
| Dinçel, VE | 1 |
| Aydoğan, NH | 1 |
| Ozsoy, A | 1 |
| Reid, IR | 1 |
| Skoglund, K | 1 |
| Hjortdal, O | 1 |
| Strømsøe, K | 1 |
| Järvinen, TL | 1 |
| Michaëlsson, K | 1 |
| Aspenberg, P | 1 |
| Sievänen, H | 1 |
| Cummings, SR | 5 |
| Jha, S | 1 |
| Wang, Z | 1 |
| Laucis, N | 1 |
| Bhattacharyya, T | 1 |
| Eriksen, EF | 1 |
| Marques, A | 1 |
| Lourenço, Ó | 1 |
| Ortsäter, G | 1 |
| Borgström, F | 1 |
| Kanis, JA | 1 |
| da Silva, JA | 1 |
| Chan, DC | 1 |
| McCloskey, EV | 1 |
| Chang, CB | 1 |
| Lin, KP | 1 |
| Lim, LC | 1 |
| Tsai, KS | 1 |
| Yang, RS | 1 |
| Huang, TW | 1 |
| Chuang, PY | 1 |
| Lee, CY | 1 |
| Huang, KC | 1 |
| Shih, HN | 1 |
| Lee, MS | 1 |
| Hsu, RW | 1 |
| Shen, WJ | 1 |
| Sobotta, HP | 1 |
| Gösling, T | 1 |
| Sánchez, A | 1 |
| Blanco, R | 1 |
| Moriwaki, K | 2 |
| Mouri, M | 1 |
| Hagino, H | 1 |
| Roerholt, C | 1 |
| Eiken, P | 3 |
| Maves, T | 1 |
| Sayed-Noor, AS | 1 |
| Sjödén, GO | 1 |
| Rabenda, V | 2 |
| Vanoverloop, J | 2 |
| Fabri, V | 2 |
| Mertens, R | 2 |
| Sumkay, F | 2 |
| Vannecke, C | 2 |
| Deswaef, A | 2 |
| Verpooten, GA | 2 |
| Reginster, JY | 2 |
| Rietbrock, S | 1 |
| Olson, M | 1 |
| van Staa, TP | 1 |
| Curtis, JR | 2 |
| Westfall, AO | 1 |
| Cheng, H | 1 |
| Saag, KG | 1 |
| Delzell, E | 2 |
| Cecilia, D | 1 |
| Jódar, E | 1 |
| Fernández, C | 1 |
| Resines, C | 1 |
| Hawkins, F | 1 |
| Iwamoto, J | 2 |
| Sato, Y | 2 |
| Takeda, T | 1 |
| Matsumoto, H | 1 |
| Yamaguchi, T | 1 |
| Sugimoto, T | 1 |
| Bize, R | 1 |
| Lamy, O | 1 |
| Peytremann-Bridevaux, I | 1 |
| Ito, M | 1 |
| Abelson, A | 1 |
| Ringe, JD | 1 |
| Gold, DT | 1 |
| Thomas, T | 1 |
| Yuan, T | 1 |
| Li, XL | 1 |
| Zhang, CQ | 1 |
| Shi, HP | 1 |
| Zeng, BF | 1 |
| Berto, P | 1 |
| Maggi, S | 1 |
| Noale, M | 1 |
| Lopatriello, S | 1 |
| Sawka, AM | 1 |
| Ismaila, N | 1 |
| Cranney, A | 2 |
| Thabane, L | 1 |
| Kastner, M | 1 |
| Gafni, A | 1 |
| Woodhouse, LJ | 1 |
| Crilly, R | 1 |
| Cheung, AM | 1 |
| Adachi, JD | 3 |
| Josse, RG | 1 |
| Papaioannou, A | 2 |
| Black, DM | 4 |
| Kelly, MP | 1 |
| Genant, HK | 2 |
| Palermo, L | 1 |
| Eastell, R | 3 |
| Bucci-Rechtweg, C | 1 |
| Cauley, J | 2 |
| Leung, PC | 1 |
| Boonen, S | 1 |
| Santora, A | 1 |
| de Papp, A | 1 |
| Bauer, DC | 4 |
| Shane, E | 1 |
| Ito, K | 1 |
| Elkin, EB | 1 |
| Girotra, M | 1 |
| Morris, MJ | 1 |
| Chan, SS | 1 |
| Rosenberg, ZS | 1 |
| Chan, K | 1 |
| Capeci, C | 1 |
| Guerra-García, MM | 1 |
| Rodríguez-Fernández, JB | 1 |
| Puga-Sarmiento, E | 1 |
| Charle-Crespo, MÁ | 1 |
| Gomes-Carvalho, CS | 1 |
| Prejigueiro-Santás, A | 1 |
| Ott, SM | 2 |
| Dell, RM | 1 |
| Pozzi, S | 1 |
| Raje, N | 1 |
| Schnitzler, V | 1 |
| Fayon, F | 1 |
| Despas, C | 1 |
| Khairoun, I | 1 |
| Mellier, C | 1 |
| Rouillon, T | 1 |
| Massiot, D | 1 |
| Walcarius, A | 1 |
| Janvier, P | 1 |
| Gauthier, O | 1 |
| Montavon, G | 1 |
| Bouler, JM | 1 |
| Bujoli, B | 1 |
| Chen, L | 1 |
| Black, D | 2 |
| Ensrud, K | 1 |
| Judd, S | 1 |
| Safford, MM | 1 |
| Schwartz, AV | 1 |
| Naranjo, A | 1 |
| Ojeda-Bruno, S | 1 |
| Francisco-Hernández, F | 1 |
| Erausquin, C | 1 |
| Rúa-Figueroa, I | 1 |
| Rodríguez-Lozano, C | 1 |
| Katz, MH | 1 |
| Gunawardena, I | 1 |
| Baxter, M | 1 |
| Rasekh, Y | 1 |
| Lin, TC | 1 |
| Yang, CY | 1 |
| Yang, YH | 1 |
| Kajino, Y | 1 |
| Kabata, T | 1 |
| Watanabe, K | 1 |
| Tsuchiya, H | 1 |
| de Vries, F | 1 |
| Rebolledo, BJ | 1 |
| Lane, JM | 1 |
| Hsiao, FY | 1 |
| Huang, WF | 1 |
| Chen, YM | 1 |
| Wen, YW | 1 |
| Kao, YH | 1 |
| Chen, LK | 1 |
| Tsai, YW | 1 |
| Curtin, BM | 1 |
| Fehring, TK | 1 |
| Rasmussen, M | 1 |
| Lange, J | 1 |
| Alzahouri, K | 1 |
| Bahrami, S | 1 |
| Durand-Zaleski, I | 1 |
| Guillemin, F | 1 |
| Roux, C | 1 |
| González López-Valcárcel, B | 1 |
| Sosa Henríquez, M | 1 |
| Pazianas, M | 1 |
| Wang, Y | 1 |
| Russell, RG | 1 |
| Poole, KE | 1 |
| Compston, JE | 2 |
| Angthong, C | 1 |
| Angthong, W | 1 |
| Seraphim, A | 1 |
| Al-Hadithy, N | 1 |
| Mordecai, SC | 1 |
| Al-Nammari, S | 1 |
| Loukota, RA | 1 |
| Musini, V | 1 |
| Mintzes, B | 1 |
| Tejani, A | 1 |
| Wright, JM | 1 |
| Komaba, H | 1 |
| Noto, S | 1 |
| Yanagisawa, S | 1 |
| Takiguchi, T | 1 |
| Inoue, H | 1 |
| Toujo, T | 1 |
| Fukagawa, M | 1 |
| Takahashi, HE | 1 |
| Harrington, JT | 1 |
| Broy, SB | 1 |
| Derosa, AM | 1 |
| Licata, AA | 1 |
| Shewmon, DA | 1 |
| Pfeifer, M | 1 |
| Begerow, B | 1 |
| Pollähne, W | 1 |
| Minne, HW | 1 |
| Deal, CL | 1 |
| Nelson, DB | 1 |
| Kerani, RP | 1 |
| Schreiner, PJ | 1 |
| Zhao, Y | 1 |
| Nevitt, MC | 2 |
| Nakamura, T | 1 |
| Miller, PD | 1 |
| Kamel, HK | 3 |
| Bida, A | 1 |
| Montagnini, M | 1 |
| Qiu, GX | 1 |
| Wu, ZH | 1 |
| Shen, JX | 1 |
| Luo, XZ | 1 |
| Tang, H | 1 |
| Wang, YP | 1 |
| Weng, XS | 1 |
| Yang, XY | 1 |
| Jin, J | 1 |
| Zhao, H | 1 |
| Tian, Y | 1 |
| Zhang, JG | 1 |
| Garnero, P | 1 |
| Hochberg, M | 1 |
| Ott, S | 1 |
| Orloff, J | 1 |
| Thompson, DE | 5 |
| Ewing, SK | 1 |
| Papapoulos, SE | 2 |
| Quandt, SA | 3 |
| Liberman, UA | 1 |
| Hochberg, MC | 2 |
| Brecht, JG | 1 |
| Kruse, HP | 1 |
| Möhrke, W | 1 |
| Oestreich, A | 1 |
| Huppertz, E | 1 |
| Bartl, R | 1 |
| Geusens, P | 1 |
| Ross, PD | 1 |
| Baran, D | 1 |
| Segal, E | 1 |
| Zinnman, C | 1 |
| Raz, B | 1 |
| Tamir, A | 1 |
| Gurevich, B | 1 |
| Siebzehner, MI | 1 |
| Ish-Shalom, S | 1 |
| Mikhail, N | 1 |
| Cope, D | 1 |
| Nyman, JA | 1 |
| Melton, LJ | 1 |
| Kane, RL | 1 |
| Muñoz, VL | 1 |
| Roger, DR | 1 |
| Valle, MB | 1 |
| García, LL | 1 |
| Hamdy, RC | 2 |
| Chesnut, CH | 1 |
| Gass, ML | 1 |
| Holick, MF | 1 |
| Leib, ES | 1 |
| Lewiecki, ME | 1 |
| Maricic, M | 1 |
| McKinney, J | 1 |
| Christoffersen, H | 1 |
| Holmegaard, SN | 1 |
| Nishii, T | 1 |
| Sugano, N | 1 |
| Miki, H | 1 |
| Hashimoto, J | 1 |
| Yoshikawa, H | 1 |
| Kanoko, T | 1 |
| Satoh, K | 1 |
| Moroni, A | 1 |
| Faldini, C | 1 |
| Hoang-Kim, A | 1 |
| Pegreffi, F | 1 |
| Giannini, S | 1 |
| Epstein, S | 1 |
| Imai, K | 1 |
| Yamamoto, S | 1 |
| Anamizu, Y | 1 |
| Horiuchi, T | 1 |
| Mamdani, M | 1 |
| Kopp, A | 1 |
| Hawker, G | 1 |
| Grima, DT | 1 |
| Thompson, MF | 1 |
| Pasquale, MK | 1 |
| Wells, GA | 1 |
| Peterson, J | 1 |
| Boucher, M | 1 |
| Shea, B | 1 |
| Robinson, V | 1 |
| Coyle, D | 1 |
| Tugwell, P | 1 |
| Liedholm, H | 1 |
| Linné, AB | 1 |
| Karpf, DB | 2 |
| Cauley, JA | 2 |
| Haskell, WL | 1 |
| Marcus, R | 1 |
| Torner, JC | 1 |
| Reiss, TF | 1 |
| Phillips, A | 1 |
| Brunelli, MP | 1 |
| Einhorn, TA | 1 |
| Col, NF | 1 |
| Pauker, SG | 1 |
| Goldberg, RJ | 1 |
| Eckman, MH | 1 |
| Orr, RK | 1 |
| Ross, EM | 1 |
| Wong, JB | 1 |
| Riancho, JA | 1 |
| Rodríguez Escolar, C | 1 |
| Fidalgo García, ML | 1 |
| Rubio Cebrián, S | 1 |
| Lambing, CL | 1 |
| Arboleya, LR | 1 |
| Morales, A | 1 |
| Fiter, J | 1 |
| Hussain, MS | 1 |
| Tariq, S | 1 |
| Perry, HM | 1 |
| Morley, JE | 1 |
| Ensrud, KC | 1 |
| Scott, JC | 1 |
| Hawkins Carranza, F | 1 |
| López Alvarez, MB | 1 |
| Pavlic, M | 1 |
| Brand, RJ | 1 |
| Netelenbos, JC | 1 |
| Duthie, EH | 1 |
| Hodsman, AB | 1 |
| Hanley, DA | 1 |
| Josse, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment[NCT02371252] | Phase 4 | 140 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| STOP Vertigo: Supplementation of Vitamin D for Termination of Recurrences From Benign Paroxysmal Positional Vertigo[NCT05863949] | 860 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | |||
| A 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial[NCT00398931] | Phase 3 | 1,099 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203] | Phase 2 | 120 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate[NCT03051620] | 142 participants (Actual) | Observational | 2017-02-01 | Completed | |||
| Finding the Optimal Resistance Training Intensity For Your Bones: A Randomized Controlled Trial (FORTIFY Bones)[NCT05541432] | 324 participants (Anticipated) | Interventional | 2022-09-13 | Recruiting | |||
| Preoperative Optimization Levosimendan in Heart Failure Patients Undergoing Hip Fracture[NCT02972918] | 19 participants (Actual) | Observational | 2014-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percent changes of bone mineral density at lumbar spine (L1-L4) from baseline to 1-year after treatment will be compared and analysed between 2 groups. (NCT02371252)
Timeframe: 1 year after treatment
| Intervention | percent (Mean) |
|---|---|
| Original Alendronate (Fosamax) | 5.54 |
| Generic Alendronate (Bonmax) | 5.39 |
Percent changes of bone mineral density at total hip from baseline to 1-year after treatment will be compared and analysed between 2 groups. (NCT02371252)
Timeframe: 1 year after treatment
| Intervention | percent (Mean) |
|---|---|
| Original Alendronate (Fosamax) | 2.48 |
| Generic Alendronate (Bonmax) | 2.52 |
"Number of participants in which CTX increased above the least significant change.~The Department of Clinical Biochemistry, Rigshospitalet, Glostrup, Denmark provided the the least significant change for p-CTX > 30%." (NCT03051620)
Timeframe: From baseline to month 24
| Intervention | participants (Number) |
|---|---|
| Study Population | 85 |
We constructed receiver operating characteristic (ROC) curves to evaluate if baseline p-CTX or baseline p-PINP at the time of alendronate discontinuation predicted TH BMD loss above the least significant change at month 12 and/or month 24 at the individual level. (NCT03051620)
Timeframe: Changes in TH BMD after one and two years.
| Intervention | percentage change (Mean) | |
|---|---|---|
| Mean change in TH BMD after one year | Mean change in TH BMD after two years | |
| Study Population | -1.14 | -2.65 |
We constructed receiver operating characteristic (ROC) curves to evaluate if carboxy-terminal collagen crosslinks (CTX) three and six months after stopping alendronate predicted TH BMD loss above the least significant change (LSC) at month 12 at the individual level. (NCT03051620)
Timeframe: Baseline and one year after baseline
| Intervention | percentage change (Mean) | ||
|---|---|---|---|
| Mean change in CTX from baseline to month 3 | Mean change in CTX from baseline to month 6 | Mean change in TH BMD from baseline to month 12 | |
| Study Population | 49 | 64 | 1.14 |
We constructed receiver operating characteristic (ROC) curves to evaluate if changes in p-CTX or p-PINP measured three and six months after stopping alendronate predicted TH BMD loss above the least significant change at month 12 and/or month 24 at the individual level. (NCT03051620)
Timeframe: one and two years after baseline
| Intervention | percentage change (Mean) | |||
|---|---|---|---|---|
| Mean change in PINP from baseline to month 3 | Mean change in PINP from baseline to month 6 | Mean change in TH BMD from baseline to month 12 | Mean change in TH BMD from baseline to month 24 | |
| Study Population | 36 | 54 | -1.14 | -2.65 |
the number of patients who lost BMD beyond the LSC at the lumbar spine (>3%) and total hip (>5%) (NCT03051620)
Timeframe: from baseline to month 24
| Intervention | participants (Number) | |
|---|---|---|
| Spine | Total hip | |
| Study Population | 21 | 26 |
28 reviews available for alendronate and Hip Fractures
| Article | Year |
|---|---|
Effect of bisphosphonate on hip fracture in patients with osteoporosis or osteopenia according to age: a meta-analysis and systematic review.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Hip Fractures; Humans; Middle A | 2022 |
Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Topics: Adult; Alendronate; Canada; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Male; Middle A | 2023 |
Cumulative network meta-analyses, practice guidelines, and actual prescriptions for postmenopausal osteoporosis: a meta-epidemiological study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcium, Dietary; Diphosphon | 2020 |
Meta-regression analysis of the efficacy of alendronate for prevention of glucocorticoid-induced fractures.
Topics: Alendronate; Bone Density Conservation Agents; Databases, Factual; Glucocorticoids; Hip Fractures; H | 2020 |
CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Dru | 2017 |
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonate | 2019 |
Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosp | 2013 |
Osteoporosis: the emperor has no clothes.
Topics: Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Evidence-Based Medicine; Female; | 2015 |
Osteoporosis: the evolution of a diagnosis.
Topics: Absorptiometry, Photon; Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Fracture | 2015 |
Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature.
Topics: Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Osteoporosis, Postmeno | 2008 |
[New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Drug Administr | 2009 |
[Bone quality].
Topics: Absorptiometry, Photon; Alendronate; Bone and Bones; Bone Density Conservation Agents; Clinical Tria | 2009 |
[Meta-analysis of alendronate preventing hip fracture risk of postmenopausal women].
Topics: Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Postmenopause; Randomi | 2009 |
A scoping review of strategies for the prevention of hip fracture in elderly nursing home residents.
Topics: Aged; Alendronate; Exercise; Fluorides; Hip Fractures; Humans; Long-Term Care; Nursing Homes; Random | 2010 |
Do bisphosphonates cause femoral insufficiency fractures?
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Femoral Fractures; Fractures | 2012 |
[Osteoporosis: prevention of bone loss and fractures].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Diseases, Metabolic; Diagnosis, D | 2002 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid | 2002 |
Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Hip Fractures; Human | 2005 |
Review of treatment modalities for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Die | 2005 |
Is cortical bone hip? What determines cortical bone properties?
Topics: Alendronate; Bone and Bones; Bone Density; Bone Remodeling; Etidronic Acid; Fractures, Spontaneous; | 2007 |
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Fractures, Spontaneous; Hip | 2008 |
Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
Topics: Adult; Aged; Alendronate; Bone and Bones; Bone Density; Calcification, Physiologic; Clinical Trials, | 1998 |
Medical management of osteoporosis. Fracture prevention.
Topics: Aged; Alendronate; Benzothiadiazines; Bone Density; Calcitonin; Calcium; Calcium, Dietary; Diuretics | 1998 |
Osteoporosis prevention, detection, and treatment. A mandate for primary care physicians.
Topics: Alendronate; Bone Development; Densitometry; Estrogen Replacement Therapy; Family Practice; Female; | 2000 |
[Effect of alendronate on bone mineral density and incidence of fractures in postmenopausal women with osteoporosis. A meta-analysis of published studies].
Topics: Alendronate; Bone Density; Calcification, Physiologic; Female; Hip Fractures; Humans; Middle Aged; O | 2000 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2000 |
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
Topics: Age Factors; Aged; Alendronate; Bone Density; Calcium Channel Blockers; Diphosphonates; Etidronic Ac | 2001 |
The underuse of therapy in the secondary prevention of hip fractures.
Topics: Accidental Falls; Alendronate; Calcium; Estrogens; Etidronic Acid; Hip Fractures; Hip Prosthesis; Hu | 2002 |
13 trials available for alendronate and Hip Fractures
| Article | Year |
|---|---|
Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bone Density; Bone Density | 2017 |
Effect of alendronate in elderly patients after low trauma hip fracture repair.
Topics: Accidental Falls; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Co | 2009 |
The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Confounding Factors, Epidemiologic; Diphosphonat | 2011 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid | 2002 |
Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT).
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alendronate; Disability Evaluation; Female; Fol | 2003 |
[Clinic effect of alendronate sodium treatment in osteoporosis patients with hip fracture].
Topics: Absorptiometry, Photon; Aged; Alanine Transaminase; Alendronate; Bone Density; Calcium; Case-Control | 2004 |
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density | 2004 |
Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Double-Blind Method; Female; Fractu | 2005 |
Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alendronate; Amino Acids; Bone Density; Bone Resorption; Calcium; Drug Ther | 2006 |
Alendronate improves screw fixation in osteoporotic bone.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Screws; C | 2007 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Estimating probability of non-response to treatment using mixture distributions.
Topics: Aged; Alendronate; Bone Density; Computer Simulation; Female; Hip Fractures; Humans; Likelihood Func | 2001 |
103 other studies available for alendronate and Hip Fractures
| Article | Year |
|---|---|
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Fema | 2023 |
Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Female; Hip Fractures; Humans; Osteop | 2020 |
Effectiveness of antiresorptive medications in women on long-term dialysis after hip fracture: A population-based cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Follow-Up Studies; H | 2020 |
Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female | 2017 |
[BISPHOSPHONATES AS A PREVENTATIVE TREATMENT FOR OSTEOPOROTIC HIP FRACTURES: A MIXED BLESSING].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Hip | 2017 |
Hip fracture risk and safety with alendronate treatment in the oldest-old.
Topics: Aged, 80 and over; Alendronate; Body Mass Index; Bone Density Conservation Agents; Case-Control Stud | 2017 |
The emperor redressed: treating osteoporosis to prevent hip fractures in the oldest old.
Topics: Aged, 80 and over; Alendronate; Hip Fractures; Humans; Osteoporosis | 2017 |
Alendronate and Hip Fracture in Patients Using Glucocorticoids.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Glucocorticoids; Hip Fractures; Humans; | 2017 |
Alendronate and Hip Fracture in Patients Using Glucocorticoids-Reply.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Glucocorticoids; Hip Fractures; Humans; | 2017 |
Alendronate Use and the Risk of Nonvertebral Fracture During Glucocorticoid Therapy: A Retrospective Cohort Study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Follow-Up Studies; Glucocorticoids; Hip | 2018 |
[Subtrochanteric pathological fracture on bisphosphonates].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Spontaneous; | 2018 |
Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture.
Topics: Aged; Aged, 80 and over; Alendronate; Cardiovascular Diseases; Cause of Death; Female; Hip Fractures | 2018 |
Reply to: Association Between Alendronate and All-Cause Mortality and Cardiovascular Mortality Among Hip Fracture: An Alternative Explanation.
Topics: Alendronate; Bone Density Conservation Agents; Cardiovascular Diseases; Hip Fractures; Humans | 2018 |
Association Between Alendronate and All-Cause Mortality and Cardiovascular Mortality Among Hip Fracture: An Alternative Explanation.
Topics: Alendronate; Cardiovascular Diseases; Hip Fractures; Humans | 2018 |
Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denmark; Denosumab; Female; Hip Fractures; Huma | 2019 |
Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; E | 2013 |
Alendronate and risk of lower limb ischemic vascular events: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Amputation, Surgical; Bone Density Conservation Agents; Cohort | 2014 |
Menopause practitioner perspective on the American Society of Bone and Mineral Research Task Force report on atypical femoral fracture.
Topics: Advisory Committees; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; | 2013 |
Bisphosphonate-induced atypical subtrochanteric femoral fracture.
Topics: Absorptiometry, Photon; Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Fema | 2013 |
Injury to the superior gluteal artery during intramedullary fixation of an atypical subtrochanteric stress fracture - a case report.
Topics: Alendronate; Arteries; Blood Transfusion; Bone Density Conservation Agents; Bone Nails; Buttocks; Fe | 2013 |
Implant failure caused by non-union of bisphosphonate-associated subtrochanteric femur fracture.
Topics: Alendronate; Bone Density Conservation Agents; Device Removal; Female; Femoral Fractures; Fracture F | 2014 |
Femoral insufficiency fractures in the elderly - excessive medial femoral bowing complicates intramedullary nailing.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Female; Femoral Fractures; Femur; Fol | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; | 2015 |
Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Female; Fract | 2015 |
[Re: Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates].
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Female; Hip Fractur | 2015 |
Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Data C | 2015 |
[Re: Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates].
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Female; Hip Fractur | 2015 |
Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analys | 2016 |
Establishing and evaluating FRAX
Topics: Age Distribution; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density Conservation Agents | 2017 |
Teriparatide Improves Fracture Healing and Early Functional Recovery in Treatment of Osteoporotic Intertrochanteric Fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcium; Female; Fracture He | 2016 |
[Atypical subtrochanteric femur fracture under alendronate therapy in spite of an intramedullar implant].
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Female; F | 2017 |
Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Con | 2017 |
Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Diphosphonates; Drug Adm | 2017 |
Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule | 2009 |
The role of managed care in the management of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Disease Management; Fem | 2005 |
Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy--a case report.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fracture Healing; Hip Fra | 2008 |
Low incidence of anti-osteoporosis treatment after hip fracture.
Topics: Aged; Alendronate; Belgium; Bone Density Conservation Agents; Cohort Studies; Databases, Factual; Di | 2008 |
The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug | 2009 |
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; F | 2009 |
[Osteoporotic fracture in menopausal women: alendronate reduces the risk].
Topics: Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Hip Fractures; Humans; Middl | 2008 |
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Meth | 2010 |
Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Costs | 2010 |
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
Topics: Alendronate; Bone Density Conservation Agents; Confidence Intervals; Diphosphonates; Female; Femoral | 2010 |
Evolving data about subtrochanteric fractures and bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Hip Fractu | 2010 |
Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Antineoplastic Agents; Bone Density; Bon | 2010 |
Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Fe | 2010 |
[Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Prescriptions; Etidronic Acid; Female; Hip | 2011 |
Bisphosphonates and atypical femoral fractures.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Hip Fractures; Humans; Imidazoles; In | 2010 |
Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Fem | 2010 |
Bisphosphonates and atypical femoral fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Femoral Fractures; H | 2010 |
Investigation of alendronate-doped apatitic cements as a potential technology for the prevention of osteoporotic hip fractures: critical influence of the drug introduction mode on the in vitro cement properties.
Topics: Adsorption; Alendronate; Apatites; Bone Cements; Calcium Phosphates; Dielectric Spectroscopy; Diphos | 2011 |
[Application of guidelines for secondary prevention of fracture and the FRAX index in patients with fragility fracture].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservatio | 2011 |
Proton pump inhibitor use and the antifracture efficacy of alendronate.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Chi-Square Distributi | 2011 |
Opportunities to decrease inappropriate uses of proton pump inhibitors: Comment on "Proton pump inhibitor use and the antifracture efficacy of alendronate".
Topics: Alendronate; Bone Density Conservation Agents; Denmark; Dose-Response Relationship, Drug; Drug Inter | 2011 |
Bisphosphonate-related subtrochanteric femoral fractures.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Hip Fractures; Human | 2011 |
Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan.
Topics: Aged; Alendronate; Analysis of Variance; Asian People; Bone Density Conservation Agents; Cohort Stud | 2011 |
Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy.
Topics: Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Middle Aged; Time Fact | 2012 |
Inverse association between duration of use of acid-suppressive medications and fracture risk.
Topics: Alendronate; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug Interactions; | 2011 |
Bilateral pathologic hip fractures associated with antiretroviral therapy: a case report.
Topics: Accidental Falls; Adenine; Alendronate; Anti-HIV Agents; Bone Density Conservation Agents; Comorbidi | 2011 |
Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Human | 2011 |
Bisphosphonate fractures as a cause of painful total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Bone D | 2011 |
[Treatment with bisphosphonates as a possible cause of bilateral spontaneous atypical femoral fracture].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Fractures, Spontaneous; Hip Fractures; | 2012 |
Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX™ thresholds for decision.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Hip Fractures; H | 2013 |
[Estimate of the 10-year risk of osteoporotic fractures in the Spanish population].
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density Conservation | 2013 |
Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Topics: Administration, Oral; Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedul | 2012 |
Bisphosphonates in the treatment of osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Osteoporosis; Tr | 2012 |
Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; F | 2011 |
Osteonecrosis of the jaw is becoming more common.
Topics: Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Osteoporosis | 2012 |
Review overemphasises benefits and downplays serious harms.
Topics: Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Osteoporosis | 2012 |
Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Diseases, Metabolic; Cost-Benefit An | 2013 |
Hip fracture patients are not treated for osteoporosis: a call to action.
Topics: Absorptiometry, Photon; Alendronate; Calcitonin; Calcium; Estrogen Antagonists; Estrogens; Hip Fract | 2002 |
[Fragility fracture and its control].
Topics: Accidental Falls; Aged; Alendronate; Female; Fractures, Spontaneous; Hip Fractures; Humans; Male; Os | 2003 |
Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis.
Topics: Alendronate; Bone Density; Bone Remodeling; Drug Therapy, Combination; Female; Hip Fractures; Humans | 2004 |
Secondary prevention of hip fractures in veterans: can we do better?
Topics: Aged; Aged, 80 and over; Alendronate; Calcium; Drug Utilization; Geriatrics; Great Lakes Region; Hip | 2004 |
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Cohort Studies; Cost-Benefit Analysis; Etidronic | 2004 |
[Update 2004. Osteoporosis--management--current status].
Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Fem | 2004 |
Second hip fracture in elderly hip fracture patients: cost and effectiveness of fracture prevention treatment.
Topics: Aged; Alendronate; Calcium; Cholecalciferol; Costs and Cost Analysis; Hip Fractures; Humans; Osteopo | 2005 |
Alendronate and vertebral fracture risk.
Topics: Alendronate; Bone Density; Data Interpretation, Statistical; Female; Femur Neck; Hip Fractures; Huma | 2005 |
Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Ambulatory Care; Bone Density Conserva | 2005 |
[Antiresorptive treatment after proximal femur fracture].
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Drug Therapy, Combination; Etidronic Acid; H | 2005 |
The patient's page. Bone health facts.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Dietary Sup | 2005 |
[Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; F | 2005 |
Does alendronate prevent collapse in osteonecrosis of the femoral head?
Topics: Adolescent; Adult; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Ag | 2006 |
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Evaluation; Etidronic A | 2007 |
Meds hiatus won't hurt your hips. Five years on, five years off: taking a break from Fosamax won't result in broken bones.
Topics: Alendronate; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Osteoporosis, Postmeno | 2007 |
[Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Etidronic Acid; Female; Fractures, Sp | 2007 |
Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy.
Topics: Aged; Alendronate; Bone and Bones; Female; Hip Fractures; Humans; Osteoporosis; Risk Factors | 2007 |
Hip fractures in users of first- vs. second-generation bisphosphonates.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Diphosphonat | 2007 |
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; E | 2008 |
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Canada; Cost-B | 2008 |
Alendronate in postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Spinal Fra | 1996 |
The Fracture Intervention Trial.
Topics: Alendronate; Bone Density; Costs and Cost Analysis; Female; Fractures, Bone; Hip Fractures; Humans; | 1997 |
Injury prevention.
Topics: Alendronate; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal | 1998 |
Prevention of hip fractures in older women: a population-based perspective.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Exercise; | 1998 |
Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.
Topics: Alendronate; Bone Density; Breast Neoplasms; Coronary Disease; Decision Support Techniques; Estrogen | 1999 |
[Number of patients to be treated and number of prevented fractures: clinical efficiency of osteoporosis treatment with diphosphonate alendronate].
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Data Interpretation, Statistical; F | 1999 |
Alendronate.
Topics: Alendronate; Bone Density; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Spinal Fract | 1999 |
[A cost-effectiveness analysis of alendronate compared to placebo in the prevention of hip fracture].
Topics: Aged; Alendronate; Cost-Benefit Analysis; Decision Support Techniques; Female; Hip Fractures; Humans | 1999 |
[Most recent study results show: the bisphosphonate alendronate works more rapidly than previously assumed].
Topics: Alendronate; Evidence-Based Medicine; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis; T | 2000 |
Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Calcium Compounds; Comorbidity; Diagnosis, D | 2000 |
[Cost effectiveness analysis of alendronate versus placebo in the prevention of hip fractures].
Topics: Alendronate; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Hip Fractures; Huma | 2000 |
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagoni | 2000 |
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
Topics: Aged; Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; | 2002 |